Search

Author/Creator Jones, Chelsea E

1. 1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy. (31st December 2020)

Authors:
Kline, Ellen G; Nguyen, Minh Hong T; McCreary, Erin K; Wildfeuer, Brett; Kohl, Josh; Hughes, Kailey L; Jones, Chelsea E; Doi, Yohei; Doi, Yohei; Shields, Ryan K
Journal:
Open forum infectious diseases
Issue:
Volume 7:Number 1(2020) Supplement
Page Start:
S663
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. (18th November 2019)

Authors:
Shields, Ryan K; McCreary, Erin K; Marini, Rachel V; Kline, Ellen G; Jones, Chelsea E; Hao, Binghua; Chen, Liang; Kreiswirth, Barry N; Doi, Yohei; Clancy, Cornelius J; Nguyen, M Hong
Journal:
Clinical infectious diseases
Issue:
Volume 71:Number 3(2020)
Page Start:
667
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. Issue 2 (23rd March 2023)

Authors:
Rogers, Tara M; Kline, Ellen G; Griffith, Marissa P; Jones, Chelsea E; Rubio, Abigail M; Squires, Kevin M; Shields, Ryan K
Journal:
JAC-antimicrobial resistance
Issue:
Volume 5:Issue 2(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗